210 Pill - blue capsule/oblong, 15mm
Generic Name: hyoscyamine/methenamine/methylene blue/phenyl salicylate/sodium biphosphate
Pill with imprint 210 is Blue, Capsule/Oblong and has been identified as Uro-458 hyoscyamine sulfate 0.12 mg / methenamine 81 mg / methylene blue 10.8 mg / phenyl salicylate 32.4 mg / sodium phosphate monobasic 40.8 mg. It is supplied by Method Pharmaceuticals, LLC.
Uro-458 is used in the treatment of Urinary Tract Infection and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Uro-458 hyoscyamine sulfate 0.12 mg / methenamine 81 mg / methylene blue 10.8 mg / phenyl salicylate 32.4 mg / sodium phosphate monobasic 40.8 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for 210
Uro-458
- Generic Name
- hyoscyamine/methenamine/methylene blue/phenyl salicylate/sodium biphosphate
- Imprint
- 210
- Strength
- hyoscyamine sulfate 0.12 mg / methenamine 81 mg / methylene blue 10.8 mg / phenyl salicylate 32.4 mg / sodium phosphate monobasic 40.8 mg
- Color
- Blue
- Size
- 15.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Urinary antispasmodics
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Method Pharmaceuticals, LLC
- National Drug Code (NDC)
- 58657-0458
- Inactive Ingredients
-
polyethylene glycol,
lactose,
crospovidone,
magnesium stearate,
silicon dioxide,
FD&C Blue No. 1
Note: Inactive ingredients may vary.
Related images for "210"
More about Uro-458 (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- Drug class: urinary antispasmodics
Patient resources
Other brands
Uribel, Uro-MP, Phosphasal, Uretron DS, ... +16 more
Professional resources
Other brands
Uribel, Phosphasal, Uretron DS, Urelle, ... +7 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.